A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The PROVE3 trial is a partially double blinded, randomized, Phase 2 research study of an
investigational drug, Telaprevir (VX-950) or Placebo, with Pegylated Interferon Alfa 2a
(Peg-IFN-alfa-2a, Pegasys®), and Ribavirin (RBV, Copegus®) in people with genotype 1
hepatitis C who have not achieved a Sustained Viral Response (SVR) with a previous treatment
of interferon therapy.